Ardelyx, Inc. ARDX

Ardelyx (ARDX) recently cut its 2026 IBSRELA revenue guidance to a range of $350 million to $370 million, down from $410 million to $430 million, citing tougher payer utilization-management hurdles that slowed new patient starts. See our latest analysis for Ardelyx. The guidance cut and lowered expectations for IBSRELA have come alongside a sharp reset in Ardelyx’s share price, with the stock down 23.43% on a 30 day share price return basis and 36.33% on a 1 year total shareholder return...

Valeris, an integrated commercialization partner helping life sciences companies connect market access, patient services, and commercial strategy, today announced the appointment of Lauren Cole as Chief Strategy Officer, reporting to Chief Commercial Officer Scott Filosi. The appointment reflects Valeris' continued investment in growth and innovation, with the patient kept at the center of every strategic decision.